What is the principal amount of the new credit facility and its maturity date?

The Second Amended and Restated Credit Agreement provides for a principal amount of $850 million with an option to increase by an additional $150 million, for a total of up to $1 billion. The maturity date for this five-year unsecured revolving credit facility is December 4, 2020.

What are the key changes to IDEXX's director election policy?

IDEXX has shifted from a plurality voting standard to a majority voting standard for directors in uncontested elections. This means a director nominee must receive more 'for' votes than 'against' votes to be elected. Additionally, incumbent directors failing to achieve majority support in an uncontested election must submit their resignation for the Board's consideration.

What are the primary uses for borrowings under the new credit facility?

Borrowings under the Second Amended and Restated Credit Agreement are designated for the general corporate purposes of IDEXX Laboratories and its subsidiaries.

Does the company's credit facility have any covenants or restrictions?

Yes, the Credit Agreement includes customary affirmative, negative, and financial covenants. Negative covenants restrict liens, indebtedness of subsidiaries, fundamental changes, investments, affiliate transactions, and other restrictive agreements. A key financial covenant involves a consolidated leverage ratio test.

IDXX 8-K: Material Agreements & Corporate Changes

Summary

IDEXX Laboratories, Inc. (IDXX) announced significant updates regarding its financing and corporate governance through an 8-K filing on December 8, 2015. The company entered into a Second Amended and Restated Credit Agreement, effectively extending its five-year unsecured revolving credit facility to mature in December 2020. This facility was increased from $700 million to $850 million, with an option to expand by an additional $150 million, bringing the potential total to $1 billion, providing substantial financial flexibility for general corporate purposes. In addition to the credit facility enhancements, IDEXX also amended its corporate governance policies. The company adopted a majority voting standard for directors in uncontested elections, a significant shift from the previous plurality standard. This change, coupled with an updated Corporate Governance Guidelines requiring director resignations if they fail to receive majority support, aims to increase accountability and shareholder influence in director elections.

Key Highlights

1IDEXX Laboratories entered into a Second Amended and Restated Credit Agreement, extending its unsecured revolving credit facility to December 4, 2020.
2The revolving credit facility was increased from $700 million to $850 million, with an option to increase by an additional $150 million to a total of $1 billion.
3Borrowings under the new credit agreement can be used for general corporate purposes of the Company and its subsidiaries.
4The credit agreement allows for borrowings in multiple currencies, including USD, CAD, Euros, and AUD, with interest rates tied to various benchmarks plus a margin based on the Company's consolidated leverage ratio.
5IDEXX amended its Amended and Restated By-Laws to implement a majority voting standard for directors in uncontested elections.
6The company also updated its Corporate Governance Guidelines to adopt a majority voting policy for directors in uncontested elections.
7Directors who fail to receive a majority of votes cast in an uncontested election will be required to tender their resignation for Board consideration.

IDEXX LABORATORIES INC /DE 8-K Report, Material Agreement (Dec 8, 2015)

Summary

Key Highlights

Frequently Asked Questions